Rapid rebound in HBV DNA in previously
undetectable hepatitis B/HIV
co-infected patients switching from tenofovir to entecavir therapy
co-infected patients switching from tenofovir to entecavir therapy
•Purpose of the study: To describe the effects
of switching from a TDF-based regimen to ETV for HBV suppression in HIV/HBV
co-infected patients with previously undetectable HBV DNA
•Baseline results:
–6 patients switched to ETV because of
nephrotoxicity to TDF
–All patients were HBeAg+ and had undetectable
HBV DNA
–5/6 patients had prior HBV DNA samples for GT
resistance testing
–100% revealed evidence of 3TC resistance
(presence of L180M and M204V)
•Outcome results:
–All patients experienced HBV rebound on
ETV
–Median time to rebound was 2 months
–Only 1 patient developed a rise in ALT
–All patients maintained virological
suppression for HIV
Hull M, et al.
9th Intl. Congress on Drug Therapy in HIV Infection. Glasgow 2008;P271.